UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 11 28, 2006

TELZUIT MEDICAL TECHNOLOGIES, INC.

(Exact name of Registrant as specified in its charter)

Commission file number 001-15034

Florida

01-0656115

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

identification no.)

5422 Carrier Drive, Suite 306

Orlando, Florida

32819

(Address of principal executive offices)

(Zip code)

(407) 354-1222

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~ITEM 1~~Item 4.01 ~~ENTRY~~Changes ~~INTO~~in ARegistrant’s ~~MATERIAL~~Certifying ~~DEFINITIVE AGREEMENT~~ Accountant

~~Reference~~Effective isJuly ~~made~~28, to2006, Telzuit Medical Technologies, Inc. (the ~~material~~“Company”) ~~terms~~engaged ~~and~~Cross, ~~conditions~~Fernandez of& ~~Mr. Jerry~~Riley, ~~Balter’s~~LLP ~~employment~~as ~~that~~its ~~are~~new ~~disclosed~~independent ~~below~~registered ~~under~~public ~~Item 5.02~~accountant ~~of this~~to ~~Current~~audit ~~Report~~the onCompany’s ~~Form~~financial ~~8-K~~statements for the year ended June 30, 2006.

~~ITEM 5.02~~During ~~DEPARTURE~~the OFtwo ~~DIRECTORS~~most ORrecent ~~PRINCIPAL~~fiscal ~~OFFICERS;~~years ~~ELECTION~~and OFthe ~~DIRECTORS~~interim period between June 30, 2006 and July 6, 2006 (the date of dismissal of the Company’s prior independent registered public accounting firm), neither the Company (nor anyone on its behalf) consulted Cross, Fernandez & Riley, LLP regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written nor oral report was provided to the Company in which a conclusion reached by the new accountant was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; ~~APPOINTMENT~~or OF(ii) ~~PRINCIPAL~~any matter that was subject to any disagreement or reportable event under Item 304(a)(1) of ~~OFFICERS~~Regulation S-B.

Departure of Principal Officer

Effective July 11, 2006, Warren D. Stowell has resigned as Telzuit Medical Technologies, Inc.’s (the “Company”) Chief Financial Officer. Mr. Stowell continues to serve as the Company’s President and Chief Executive Officer, and as a member of the Board of Directors.

Appointment of Principal Officer

Jerry Balter has been appointed as the Company’s Chief Financial Officer effective July 11, 2006. Mr. Balter, age 53, has more than 25 years of experience in investment baking. From 2005 to date, Mr. Balter served as the Chief Financial Officer of The Ulysses Group, a business development consulting practice co-founded by Mr. Balter in 1986. From 2004 until 2005, Mr. Balter served as a Managing Director of Punk Ziegel & Company. From 2003 until 2004, he worked as a Managing Director of Aurora Capital, LLC, where he focused his efforts on early stage biotechnology companies. Prior to that, Mr. Balter founded and managed The New Zealand Seed Fund from 1999 until 2003. Mr. Balter received his B.S. in biochemistry from Columbia University and an M.B.A. in finance from New York University.

There are no family relationships among Mr. Balter and any of the Company’s directors or executive officers.

On July 13, 2006, the Company entered into a three-year employment agreement with Mr. Balter (the “Agreement”). Under the terms of the Agreement, Mr. Balter is entitled to receive a salary of $150,000 per annum. In addition, he is entitled to receive a stock option to purchase one million shares of the Company’s common stock at an exercise price of $0.50, subject to a vesting schedule of 25% as of the effective date of the Agreement and 25% at each anniversary thereof. In addition, under the terms of the Agreement, Mr. Balter is entitled to receive (a) heath benefits and coverage; and (b) a monthly car allowance.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~Telzuit Medical Technologies, Inc.~~

Telzuit Medical Technologies, Inc.

~~(Registrant)~~

(Registrant)

Date: July 17, 2006

/s/ James P. Tolan

Date: July 31, 2006

/s/ Warren Stowell

James P. Tolan Vice President and Secretary

Warren D. Stowell President and Chief Executive Officer

Filing Compare · Telzuit Medical Technologies, Inc.